AEON Biopharma (NASDAQ:AEON - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $18.00 price objective on the stock. HC Wainwright's target price would suggest a potential upside of 165.10% from the company's current price.
AEON Biopharma Price Performance
Shares of NASDAQ AEON traded down $0.10 on Wednesday, hitting $6.79. The company had a trading volume of 43,202 shares, compared to its average volume of 52,153. AEON Biopharma has a 12-month low of $3.37 and a 12-month high of $17.17. The business has a 50 day moving average of $10.74 and a two-hundred day moving average of $7.79.
AEON Biopharma (NASDAQ:AEON - Get Free Report) last released its quarterly earnings results on Friday, March 29th. The company reported ($0.71) EPS for the quarter. On average, equities analysts anticipate that AEON Biopharma will post -1.54 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in AEON Biopharma by 8.3% during the 4th quarter. Vanguard Group Inc. now owns 209,785 shares of the company's stock worth $1,510,000 after buying an additional 16,091 shares during the period. Northern Trust Corp grew its stake in shares of AEON Biopharma by 53.4% during the fourth quarter. Northern Trust Corp now owns 49,819 shares of the company's stock valued at $359,000 after acquiring an additional 17,341 shares in the last quarter. Formidable Asset Management LLC purchased a new stake in shares of AEON Biopharma during the third quarter worth about $360,000. Finally, Atalaya Capital Management LP acquired a new position in shares of AEON Biopharma in the third quarter worth about $19,827,000. 22.78% of the stock is currently owned by hedge funds and other institutional investors.
About AEON Biopharma
(
Get Free Report)
AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.
Recommended Stories
Before you consider AEON Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AEON Biopharma wasn't on the list.
While AEON Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
